Ads
related to: do statins increase life expectancy in adults over 65 women in californiaconsumereview.org has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
When examining the cost-effectiveness of statin use in older adults, the researchers report that statins were cost-effective, with the cost per quality-adjusted life years gained below £3,502 ...
Statins appear to be effective at preventing cardiovascular disease and death in older adults, according to new research. Most clinical trials evaluating statins have not included people 75 and ...
Recent estimates show that in 2019, the heart disease-related mortality rate among people ages 60 to 80 was 77–80%, and 85% for people over 80. For people ages 40 to 60, 35–40% died of heart ...
They recommended selective use of low-to-moderate doses statins in the same adults who have a calculated 10-year cardiovascular disease event risk of 7.5–10% or greater. [22] In people over the age of 70, statins decrease the risk of cardiovascular disease but only in those with a history of heavy cholesterol blockage in their arteries. [24]
In this trial, which lasted 5.4 years, overall mortality was reduced by 13% and cardiovascular mortality was reduced by 18%. People receiving simvastatin experienced 38% fewer nonfatal heart attacks and 25% fewer strokes. [12] Statins in general have been proposed as beneficial in reducing the progression of Age-related Macular Degeneration ...
The life expectancy in some states has fallen in recent years; for example, Maine's life expectancy in 2010 was 79.1 years, and in 2018 it was 78.7 years. The Washington Post noted in November 2018 that overall life expectancy in the United States was declining although in 2018 life expectancy had a slight increase of 0.1 and bringing it to ...
The study authors reported that for people younger than 60, 65% of women and 79% of men received cholesterol-lowering medication after diagnosis. Three years later, 52% of women and 78% of men ...
[5] [6] [7] The study's authors estimated that the number needed to treat with rosuvastatin to prevent one cardiovascular event was 95 over two years, extrapolated to 25 over five years. The trial was stopped early, after just 1.9 years median duration, by the study's Independent Data Monitoring Board, because the interim results met the study ...